Inagaki-Kawata, Yukiko
Yoshida, Kenichi http://orcid.org/0000-0003-4612-2778
Kawaguchi-Sakita, Nobuko
Kawashima, Masahiro
Nishimura, Tomomi
Senda, Noriko
Shiozawa, Yusuke
Takeuchi, Yasuhide
Inoue, Yoshikage
Sato-Otsubo, Aiko
Fujii, Yoichi
Nannya, Yasuhito
Suzuki, Eiji
Takada, Masahiro
Tanaka, Hiroko http://orcid.org/0000-0001-9634-8922
Shiraishi, Yuichi
Chiba, Kenichi
Kataoka, Yuki
Torii, Masae
Yoshibayashi, Hiroshi
Yamagami, Kazuhiko
Okamura, Ryuji
Moriguchi, Yoshio http://orcid.org/0000-0002-9268-5531
Kato, Hironori
Tsuyuki, Shigeru
Yamauchi, Akira
Suwa, Hirofumi
Inamoto, Takashi
Miyano, Satoru
Ogawa, Seishi http://orcid.org/0000-0002-7778-5374
Toi, Masakazu http://orcid.org/0000-0003-1488-9958
Article History
Received: 23 March 2020
Accepted: 15 September 2020
First Online: 16 October 2020
Competing interests
: The authors declare the following competing interests: Masakazu Toi: Research grant: Astra Zeneca, Pfizer, Eisai, Chugai Pharma, Astellas Pharma, Daiichi Sankyo, Taiho Pharmaceutical, C & C Research Laboratories, Ono Pharmaceutical, Shimadzu, Nippon-Kayaku, AFI technology, Japan Breast Cancer Research Group. Consulting or Advisory Role: Daiichi Sankyo, Kyowa Hakko Kirin, Athenex Oncology and Bertis. Honoraria as lecture fee: AstraZeneca, Bayer, C & C Research Laboratories, Chugai Pharma, Daiichi Sankyo, Eisai, Eli Lilly, Genomic Health, Konica Minolta, Kyowa Hakko Kirin, MSD, Novartis, Pfizer, Sanofi, Shimadzu, Taiho Pharmaceutical, Takeda, Yakult. Travel and accommodation expenses: Genomic Health Inst., Eli Lilly and companies. Others: A member of board of directors (no salary) Organization for Oncology and Translational Research, Japan Breast Cancer Research Group and Kyoto Breast Cancer Research Network.